Literature DB >> 27265835

Pediatric Malignant Bone Tumors: A Review and Update on Current Challenges, and Emerging Drug Targets.

Twana M Jackson1, Mark Bittman2, Linda Granowetter3.   

Abstract

Osteosarcoma (OS) and the Ewing sarcoma family of tumors (ESFT) are the most common malignant bone tumors in children and adolescents. While significant improvements in survival have been seen in other pediatric malignancies the treatment and prognosis for pediatric bone tumors has remained unchanged for the past 3 decades. This review and update of pediatric malignant bone tumors will provide a general overview of osteosarcoma and the Ewing sarcoma family of tumors, discuss bone tumor genomics, current challenges, and emerging drug targets.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Mesh：

Year:  2016        PMID： 27265835     DOI： 10.1016/j.cppeds.2016.04.002

Source DB:  PubMed          Journal:  Curr Probl Pediatr Adolesc Health Care        ISSN： 1538-3199


  17 in total

1.  SUMO-specific protease 2 (SENP2) functions as a tumor suppressor in osteosarcoma via SOX9 degradation.

Authors:  Hong Pei; Liang Chen; Quan-Ming Liao; Ke-Jun Wang; Shun-Guang Chen; Zheng-Jie Liu; Zhi-Cai Zhang
Journal:  Exp Ther Med       Date:  2018-10-09       Impact factor: 2.447

2.  Comprehensive Analysis of Regulatory Networks of m6A Regulators and Reveals Prognosis Biomarkers in Sarcoma.

Authors:  Boran Pang; Dinghao Luo; Bojun Cao; Wen Wu; Lei Wang; Yongqiang Hao
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

3.  Predictors of Chemotherapy Induced Adverse Events in Pediatric Osteosarcoma Patients.

Authors:  Phitjira Sanguanboonyaphong; Patcharee Komvilaisak; Kunanya Suwannaying; Jukapun Yoodee; Manit Saeteaw; Suthan Chanthawong; Suphat Subongkot
Journal:  Asian Pac J Cancer Prev       Date:  2022-01-01

4.  Ewing Sarcoma of the Pelvis with an Atypical Radiographic Appearance: A Mimicker of Non-malignant Etiologies.

Authors:  Miguel Flores; Anthony Caram; Edward Derrick; John D Reith; Laura Bancroft; Kurt Scherer
Journal:  Cureus       Date:  2016-09-18

5.  Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.

Authors:  Yongshuang Li; Hao Hou; Peng Zhang; Zhiyu Zhang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

6.  Silencing of estrogen receptor β promotes the invasion and migration of osteosarcoma cells through activating Wnt signaling pathway.

Authors:  Yiping Zhang; Changchang Yin; Xufeng Zhou; Yahua Wu; Lili Wang
Journal:  Onco Targets Ther       Date:  2019-08-22       Impact factor: 4.147

7.  YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells.

Authors:  Siew Mei Ong; Kohei Saeki; Mun Keong Kok; Takayuki Nakagawa; Ryohei Nishimura
Journal:  J Vet Med Sci       Date:  2019-07-15       Impact factor: 1.105

8.  Anti-proliferative, pro-apoptotic and anti-invasive effect of EC/EV system in human osteosarcoma.

Authors:  Francesca Punzo; Chiara Tortora; Daniela Di Pinto; Iolanda Manzo; Giulia Bellini; Fiorina Casale; Francesca Rossi
Journal:  Oncotarget       Date:  2017-04-13

9.  LAMP3 plays an oncogenic role in osteosarcoma cells partially by inhibiting TP53.

Authors:  Shaoxian Liu; Junyi Yue; Wei Du; Jian Han; Weidong Zhang
Journal:  Cell Mol Biol Lett       Date:  2018-07-11       Impact factor: 5.787

10.  A Hypoxia Gene-Based Signature to Predict the Survival and Affect the Tumor Immune Microenvironment of Osteosarcoma in Children.

Authors:  Feng Jiang; Xiao-Lin Miao; Xiao-Tian Zhang; Feng Yan; Yan Mao; Chu-Yan Wu; Guo-Ping Zhou
Journal:  J Immunol Res       Date:  2021-07-15       Impact factor: 4.818
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.